The global CIS insulin market is poised for consistent growth, reaching an estimated value of US$ 465 million by 2022, driven by the increasing number of diabetic patients worldwide. From 2022 to 2032, the market is projected to expand at a compound annual growth rate (CAGR) of 2.7%, achieving a valuation of approximately US$ 600 million by the end of the forecast period.
As of 2021, the market was valued at US$ 455 million and experienced a year-on-year growth rate of 2.2% in 2022. The steady growth reflects the rising prevalence of diabetes globally and the increasing demand for effective insulin solutions to manage blood sugar levels. CIS insulin, a key therapeutic product for diabetes management, continues to gain traction due to its efficacy and growing adoption among patients and healthcare providers.
Healthcare advancements and improved access to diabetic care, particularly in emerging markets, are expected to further bolster the demand for CIS insulin. Efforts to enhance awareness about diabetes management and the availability of advanced insulin products are anticipated to contribute to the market’s steady expansion.
Get Complete Full Report – https://www.futuremarketinsights.com/reports/cis-insulin-market
Key Takeaways:
- The global CIS insulin market is valued at US$ 465 million in 2022 and is projected to reach US$ 600 million by 2032, growing at a CAGR of 2.7%.
- Rising diabetes prevalence worldwide is a primary driver for the increasing demand for CIS insulin.
- The market experienced a year-on-year growth rate of 2.2% from 2021 to 2022, reflecting the steady adoption of CIS insulin therapies.
- Advancements in diabetes care and increased awareness of effective treatment options are expected to support sustained market growth.
The CIS insulin market will continue to play a critical role in addressing the growing diabetes burden globally, providing essential solutions for effective disease management and improving patient outcomes.
Who are the Leading Players in CIS Insulin Market?
Some of the leading cis insulin include Novo Nordisk, Sanofi, Eli Lilly, Bristol-Myers Squibb and Novartis among others. These key CIS Insulin providers are adopting various strategies such as new product launches and approvals, partnerships, collaborations, acquisitions, mergers, etc. to increase their sales and gain a competitive edge in the global CIS Insulin market.
- In June 2022– Lilly presented the new mechanism of action data and new analyses of of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes at the American Diabetes Association’s® 82nd Scientific Sessions.
- In November 2021 – Novo Nordisk announced the acquisition of Dicerna Pharmaceuticals (Dicerna) to discover and develop RNAi therapies using Dicerna’s proprietary GalXC™ RNAi platform technology.
- In February 2022 — Novartis India Limited (NIL) announced an exclusive sales and distribution agreement with Dr. Reddy’s Laboratories (Dr. Reddy’s) for a few of its Established Medicines which includes the Voveran range, the Calcium range and Methergine.
- In January 2022– Bristol Myers Squibb and Century Therapeutics announced collaboration and license agreement develop and commercialize up to four induced pluripotent stem cell (“iPSC”) derived, engineered natural killer cell (“iNK”) and / or T cell (“iT”) programs for hematologic malignancies and solid tumors.
Key Companies Profiled
- Sanofi
- Eli Lilly
- Bristol-Myers Squibb
- Novartis
- Takeda Pharmaceuticals
- Boehringer Ingelheim
- Biocon
- Dongbao Enterprise Group Co. Ltd.
- Merck KGaA
- Oramed Pharmaceuticals Inc.
- Halozyme Therapeutics
- Wanbang Biopharma
- Xinbai Pharmaceutical
- Indrar
- Farmak
Key Segments Profiled in the CIS Insulin Industry Survey
CIS Insulin Market by Product Type:
- Rapid Acting CIS Insulin
- Long Acting CIS Insulin
- Premixed CIS Insulin
- Premixed Analog CIS Insulin
- Short-Acting CIS Insulin
- Intermediate-Acting CIS Insulin
CIS Insulin Market by Application:
- CIS Insulin for treating Type I and Other Diabetes
- CIS Insulin for treating Type II Diabetes
CIS Insulin Market by Source:
- Human Recombinant CIS Insulin
- Analogs-based CIS Insulin
CIS Insulin Market by Region:
- North America CIS Insulin Market
- Latin America CIS Insulin Market
- Europe CIS Insulin Market
- Asia & Pacific CIS Insulin Market
- Middle East & Africa (MEA) CIS Insulin Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
